1
|
Al Nassan A, Bazzeh F, Sultan I. Aprepitant for severe refractory pruritus in a patient with relapsed Hodgkin lymphoma. Pediatr Blood Cancer 2024; 71:e30826. [PMID: 38146019 DOI: 10.1002/pbc.30826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/15/2023] [Revised: 12/01/2023] [Accepted: 12/06/2023] [Indexed: 12/27/2023]
Affiliation(s)
- Anwar Al Nassan
- Department of Pediatrics, King Hussein Cancer Center, Amman, Jordan
| | - Faiha Bazzeh
- Department of Pediatrics, King Hussein Cancer Center, Amman, Jordan
- Department of Pediatrics, Jordan University Hospital, Amman, Jordan
| | - Iyad Sultan
- Department of Pediatrics, King Hussein Cancer Center, Amman, Jordan
- Department of Pediatrics, Jordan University Hospital, Amman, Jordan
- Artificial Intelligence and Data Innovation Office, King Hussein Cancer Center, Amman, Jordan
| |
Collapse
|
2
|
Flattmann FE, Mohiuddin FS, Singh A, Tandon A, Lockett SJ, Hirsch JD, Mosieri CN, Kaye AM, Varrassi G, Ahmadzadeh S, Shekoohi S, Kaye AD. Odevixibat: A Novel Bile Salt Inhibitor Treatment for Pruritus in Progressive Familial Intrahepatic Cholestasis. Cureus 2024; 16:e56886. [PMID: 38659510 PMCID: PMC11042757 DOI: 10.7759/cureus.56886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Accepted: 03/25/2024] [Indexed: 04/26/2024] Open
Abstract
Chronic pruritus is defined as an itch lasting greater than six weeks. It can manifest from a wide variety of etiologies, as many different substances can act as pruritogens, such as steroids, histamine, progesterone, endogenous opioids, and serotonin. In the setting of cholestatic liver disease, increased bile acids play a major role in chronic pruritus. The itching in cholestatic liver disease is worsened in intensity at night and localized frequently to the palms, soles, knees, and other pressure sites. It can be hard to manage, affecting the quality of sleep and causing irritability, poor attention, and, in some cases, depression. One such disease that results from chronic pruritus is progressive familial intrahepatic cholestasis (PFIC), a group of uncommon hereditary disorders that affects the formation of bile and its outflow from the liver. Previously, the drug ursodeoxycholic acid was used to help manage pruritus or surgical procedures, e.g., partial external biliary diversion or partial internal biliary diversion, to help control complications of the disease. This literature review will discuss three clinical studies covering the effectiveness of odevixibat in treating pruritus in patients with PFIC. Odevixibat (Bylvay) is an oral drug that has been FDA-approved to treat pruritus in patients three months of age and older with PFIC. Odevixibat prevents the reabsorption of bile salts in the intestines, resulting in decreased levels of bile salts via their excretion in stool. Several studies have determined that the drug is well tolerated and provides a nonsurgical, pharmacological treatment alternative for those with PFIC.
Collapse
Affiliation(s)
- Farrah E Flattmann
- School of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA
| | - Farhan S Mohiuddin
- School of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA
| | - Anjuni Singh
- School of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA
| | - Anamika Tandon
- School of Medicine, Louisiana State University Health Sciences Center, New Orleans, USA
| | - Stewart J Lockett
- School of Medicine, Louisiana State University Health Sciences Center, Shreveport, USA
| | - Jon D Hirsch
- Department of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA
| | - Chizoba N Mosieri
- Department of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA
| | - Adam M Kaye
- Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences University of the Pacific, Stockton, USA
| | | | - Shahab Ahmadzadeh
- Department of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA
| | - Sahar Shekoohi
- Department of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA
| | - Alan D Kaye
- Department of Anesthesiology, Louisiana State University Health Sciences Center, Shreveport, USA
| |
Collapse
|